Article Text

Download PDFPDF
The Antifibrogenic Potential of PPARγ Ligands in Pulmonary Fibrosis
  1. Patricia J. Sime, MD, FRCP
  1. From the Department of Environmental Medicine and the Division of Pulmonary and Critical Care Medicine, University of Rochester School of Medicine, Rochester, NY.
  1. This study was supported by the National Institutes of Health (Grants HL075432, ES01247, HL088325, HL04492, and 1KL2RR024136), the National Institute of Environmental Health Sciences (Training Grant ES-07026 and Center Grant P30ES01247), and the Connor Fund.
  2. Reprints: Patricia J. Sime, MD, FRCP, Department of Environmental Medicine and the Division of Pulmonary and Critical Care Medicine, University of Rochester School of Medicine, 601 Elmwood Ave (Box 692), Rochester, NY 14642. E-mail: Patricia_sime{at}


Pulmonary fibrosis is characterized by the accumulation of fibroblasts, myofibroblasts, collagen, and other extracellular matrix proteins in the interstitium of the lung, with subsequent scarring and destruction of the alveolar capillary interface. In some cases, pulmonary fibrosis is preceded by lung inflammation and can be treated with anti-inflammatory therapies. However, idiopathic pulmonary fibrosis is characterized by a relative paucity of underlying inflammation and currently has no effective treatment. There is increasing evidence that the transcription factor peroxisome proliferator-activated receptor (PPAR) γ plays an important role in controlling cell differentiation and that PPARγ ligands can modify inflammatory and fibrotic responses. Peroxisome proliferator-activated receptor γ ligands, including the thiazolidinedione class of antidiabetic drugs and novel triterpenoid compounds derived from oleanic acid, inhibit TGF-β-stimulated profibrotic differentiation of lung fibroblasts in vitro and reduce lung scarring in animal models of fibrosis. The mechanism of action of the PPARγ ligands is under investigation but seems to involve both PPARγ-dependent and PPARγ-independent pathways. These in vitro and in vivo data highlight the potentially exciting role of PPARγ ligands as novel therapies for fibrosis of the lung and other organ systems prone to scarring. Many of the synthetic PPARγ ligands are orally active, and several are currently available and Food Drug Administration approved for use in therapy of type 2 diabetes. Further research is urgently required to more clearly elucidate the mechanism of action of these drugs and to develop more potent antifibrotic agents for patients with scarring diseases for whom there are currently few effective therapies.

Key Words
  • PPAR
  • pulmonary fibrosis
  • TGF-β
  • PPARγ ligands

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.